Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US

ClinicoEconomics and Outcomes Research

Volumn 6, Issue 1, 2013, Pages 11-20

  Bonafede, Machaon M ^a   Johnson, Barbara H ^a   Watson, Crystal ^b  

^a IBM WATSON HEALTH   (United States)

^b BIOGEN   (United States)

Author keywords

Health care costs; Health care resource utilization; Multiple sclerosis; Natalizumab

Indexed keywords

BENZODIAZEPINE; BETA1A INTERFERON; CORTICOSTEROID; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDY; YOUNG ADULT;

EID: 84890940577     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S55779     Document Type: Article

References (28)

1. Pelletier D, Hafer DA. Fingolimod for multiple sclerosis. N Engl J Med. 2012;366:339-347.
2. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129:606-616.
3. Sadovnick AD, Ebers GC, Wilson RW, Paty DW. Life expectancy in patients attending multiple sclerosis clinics. Neurology. 1992;42:991-994.
4. Brønnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain. 2004;127:844-850.
5. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502-1517.
6. Bosca I, Coret F, Valero C, et al. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon. Mult Scler. 2008;14:636-639.
7. Elovaara I. Early treatment in multiple sclerosis. J Neurol Sci. 2011;311:S24-S28.
8. McDonald WI, Compston A, Edan G. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol. 2001;50:121-127.
9. Polman CH, O'Connor P W, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899-910.
10. Hutchinson M, Kappos L, Calabresi P, et al. The effcacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009;256:405-415.
11. Weinstock-Guttman B, Galetta SL, Giovannoni G, et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. J Neurol. 2012;259:898-905.
12. Tyas D, Kerrigan J, Russell N, Nixon R. The distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity? Value Health. 2007;10:386-389.
13. Naci H, Fleurence R, Birt J, Duhig A. Economic burden of multiple sclerosis: a systematic review of the literature. Pharmacoeconomics. 2010;28:363-379.
14. Bourdette DN, Prochazka AV, Mitchell W, Licari P, Burks J. Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. VA Multiple Sclerosis Rehabilitation Study Group. Arch Phys Med Rehabil. 1993;74:26-31.
15. O'Brien JA, Ward AJ, Patrick AR, Caro J. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res. 2003;3:17.
16. Pill M, Gilkin B. Measuring the impact of natalizumab therapy on health care utilization in a commercially managed multiple sclerosis population. Poster presented at ISPOR 16th Annual International Meeting, Baltimore, MD, May 21-25, 2011. Value Health. 2011;14:A1-A214.
17. Pill M, Gilkin B. Economic trends associated with natalizumab therapy in a commercially managed multiple sclerosis population. Poster presented at ISPOR 16th Annual International Meeting, Baltimore, MD, May 21-25, 2011. Value Health. 2011;14:A1-A214.
18. Prosperini L, Gianni C, Leonardi L, et al. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Mult Scler. 2012;18:64-71.
19. Castillo-Trivino T, Mowry EM, Gajofatto A, et al. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. Plos One. 2011;6:e16664.
20. Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics. 2008;26:617-627.
21. Chiao E, Meyer K. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis. Curr Med Res Opin. 2009;25:1445-1454.
22. Bakhshai J, Bleu-Lainé R, Jung M, et al. The cost effectiveness and budget impact of natalizumab for formulary inclusion. J Med Econ. 2010;13:63-69.
23. O'Day K, Meyer K, Miller RM, Agarwal S, Franklin M. Cost-effectiveness of natalizumab versus fngolimod for the treatment of relapsing multiple sclerosis. J Med Econ. 2011;14:617-627.
24. Sharac J, McCrone P, Sabes-Figuera R. Pharmacoeconomic considerations in the treatment of multiple sclerosis. Drugs. 2010;70: 1677-1691.
25. Owens GM, Olvey EL, Skrepnek GH, Pill M W. Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies. J Manag Care Pharm. 2013;19:S41-S53.
26. Rio J, Porcel J, Téllez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler. 2005;11:306-309.
27. O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler. 2005;11:46-50.
28. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability Brain. 2010;133:1914-1929.